Valuation: EyePoint, Inc.

Market Cap 3.5Cr 3.18Cr 2.94Cr 2.65Cr 5.01Cr 328.63Cr 5.18Cr 35Cr 14Cr 176.36Cr 13Cr 13Cr 558.62Cr P/E 2026 *
-0.08x
P/E 2027 * -0.18x
Enterprise Value -30Cr -27Cr -25Cr -22Cr -42Cr -2.78TCr -44Cr -298.51Cr -118.28Cr -1.49TCr -110.96Cr -108.62Cr -4.72TCr EV / Sales 2026 *
-152x
EV / Sales 2027 * -190x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
1 day+0.52%
1 week-15.00%
Current month-11.71%
1 month-89.71%
3 months-97.91%
6 months-97.51%
Current year-98.32%
1 week 0.28
Extreme 0.2845
0.41
1 month 0.28
Extreme 0.2845
0.6
Current year 0.28
Extreme 0.2845
18.87
1 year 0.28
Extreme 0.2845
19.11
3 years 0.28
Extreme 0.2845
30.99
5 years 0.28
Extreme 0.2845
30.99
10 years 0.28
Extreme 0.2845
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Others

Chief Financial Officer

-1,39,906 0.1669%
18/08/26 Buy

Director

10,600 0.0126%
10/07/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
+0.52%-15.00%-97.34%-95.02% 3.5Cr
-0.82%+1.40%+39.64%+143.17% 1,27500Cr
-1.12%+0.16%+44.21%+88.24% 68TCr
-0.16%+0.43%+26.76%+113.01% 52TCr
-0.50%+1.52%+42.03%+71.68% 39TCr
-2.23%-2.89%+55.47%+41.64% 36TCr
-1.28%-0.12%+26.98%+59.71% 31TCr
-1.47%-0.23%+1.91%+35.01% 29TCr
-0.72%-0.63%+37.29%+71.87% 25TCr
-0.30%-1.03%+34.04%+124.88% 21TCr
Average -0.83%-1.04%+21.10%+65.42% 43TCr
Weighted average by Cap. -0.84%+0.76%+36.48%+97.47%

Financials

2026 *2027 *
Net sales 19.41L 17.63L 16.29L 14.71L 27.77L 18Cr 28.74L 1.96Cr 77.62L 9.78Cr 72.82L 71.28L 31Cr 9L 8L 8L 7L 13.14L 8.62Cr 13.6L 92.67L 36.72L 4.63Cr 34.45L 33.72L 15Cr
Net income -34Cr -31Cr -29Cr -26Cr -49Cr -3.19TCr -50Cr -342.92Cr -135.87Cr -1.71TCr -127.47Cr -124.77Cr -5.42TCr -19Cr -17Cr -16Cr -15Cr -27Cr -1.8TCr -28Cr -193.74Cr -77Cr -967.09Cr -72Cr -70Cr -3.06TCr
Net Debt -33Cr -30Cr -28Cr -25Cr -47Cr -3.11TCr -49Cr -333.84Cr -132.28Cr -1.67TCr -124.1Cr -121.47Cr -5.28TCr -21Cr -19Cr -18Cr -16Cr -30Cr -1.97TCr -31Cr -211.78Cr -84Cr -1.06TCr -79Cr -77Cr -3.35TCr
Projected Income Statement - Annual - EyePoint, Inc.
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
16/26/16 $0.3076 +0.52% 65,46,986
13/26/13 $0.3060 -4.23% 30,86,415
12/26/12 $0.3195 -10.40% 59,67,722
11/26/11 $0.3566 -11.75% 63,46,795
10/26/10 $0.4041 +11.66% 46,06,563
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - EyePoint, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
0.3076USD
Average target price
8.312USD
Spread / Average Target
+2,602.37%
  1. Stock Market
  2. Stocks
  3. EYPT Stock